MIT Technology Review @techreview A media company making technology a greater force for good. Get our journalism: Nov. 19, 2019 1 min read

The era of editing human genes to treat inherited disease has arrived. 

A pair of biotech companies that say they’ve eliminated painful symptoms from two patients with blood diseases. 

The beta thalassemia patient, for instance, who lives in Europe, used to receive about 16 blood transfusions a year but hasn’t needed one since the treatment.

According to @NPR, the sickle-cell patient no longer suffers from pain attacks.

“This preliminary data shows for the first time that gene editing has actually helped a patient with sickle-cell disease” - Haydar Frangoul of the @SarahCannonDocs 

*Both patients did suffer some serious side effects, because their immune systems needed to be mostly destroyed with chemotherapy before the repaired bone marrow cells were reinfused. 

*For now, the biotechs don’t want to talk about the costs. Samarth Kulkarni, CEO of CRISPR Therapeutics, told @Forbes it is “too early to contemplate any sort of pricing decisions.” 

You can follow @techreview.


Tip: mention @threader_app on a Twitter thread with the keyword “compile” to get a link to it.

Enjoy Threader? Sign up.

Threader is an independent project created by only two developers. The site gets 500,000+ visits a month and our iOS Twitter client was featured as an App of the Day by Apple. Running this space is expensive and time consuming. If you find Threader useful, please consider supporting us to make it a sustainable project.